What Citrato De Fentanilo treats: Main Uses and Benefits

Citrato De Fentanilo is applied in clinical settings that involve acute or unstable symptom patterns, where supportive, strong relief is needed. This medication is used for managing symptoms related to physical discomfort and to support sedation during and after medical procedures. It is relevant for easing intense manifestations across several domains, primarily managing chronic severe pain, addressing breakthrough pain episodes, and serving as an adjunct to general and regional anesthesia.

In situations where conditions produce significant symptomatic burden, the benefit provides support that helps ease the overall symptom burden and assists with maintaining comfort during periods of heightened symptoms. The medication is commonly used when symptoms intensify, such as during the postoperative recovery or when severe flares suddenly overwhelm a patient's pain regimen.

---

Key Focus: Symptom Management
Symptom Severity Relevant	Severe, uncontrollable, and episodic pain flares
Primary Clinical Contexts	Perioperative care, chronic pain, and anesthesia adjunct
Primary Symptomatic Benefit	Helps ease overall symptom burden and supports patient comfort

---

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who can and cannot use Citrato De Fentanilo — Official Regulatory Information

Contraindicated Populations

Classification	Population/Condition
Absolute	Non-opioid tolerant patients (risk of fatal respiratory depression)
Absolute	Patients with severe respiratory depression or acute/severe bronchial asthma
Absolute	Patients with known or suspected paralytic ileus or gastrointestinal obstruction
Prohibited Use	Management of acute, short-term, or mild pain (for non-injectable forms)
Prohibited Use	Use in patients who have received MAO inhibitors within 14 days

Age and Physiological Status Rules

Population Group	Eligibility Status
Adults (Opioid Tolerant)	Allowed for severe, persistent pain (for non-injectable forms)
Pediatric Use	Safety and efficacy not established in children under 16 years for many transmucosal forms
Geriatric Use	Requires appropriate initial dose reduction and increased caution
Pregnancy	Not recommended; may cause fetal harm and Neonatal Opioid Withdrawal Syndrome (NOWS)
Lactation	Not recommended as the substance is excreted into human milk

Condition-Specific Restrictions

Use requires caution in patients with: severe hepatic impairment (liver dysfunction), severe renal impairment (kidney dysfunction), increased intracranial pressure, or head injury. These populations must be monitored closely due to the potential for prolonged effects or exacerbation of the underlying condition.

---

Connection to the Overall Eligibility Profile

Official regulatory documents define Citrato De Fentanilo eligibility through a highly restrictive framework, classifying its use as contraindicated for any individual who is not already tolerant to opioids. Furthermore, patients with severe respiratory or gastrointestinal compromise are absolutely excluded. The remaining eligibility profile specifies conditional use only in adults meeting the opioid-tolerance criteria, or in specific pediatric populations for anesthesia, requiring documented caution for older adults or those with organ function impairment.

Interactions with other medicines and products

The use of Citrato De Fentanilo with other medications must be approached with caution due to the potential for serious or life-threatening interactions, which are mainly categorized by effects on the central nervous system (CNS) and drug metabolism.

Central Nervous System (CNS) Depressants

Co-administration with CNS depressants, including benzodiazepines, other sedatives (such as anxiolytics, tranquilizers, and muscle relaxants), general anesthetics, and alcohol, carries a significant risk. This combination can result in enhanced CNS effects, leading to profound sedation, severe respiratory depression, coma, and death. Prescribing together is generally avoided or reserved for cases where alternatives are inadequate, requiring the lowest necessary doses and close patient monitoring.

Effects on Drug Metabolism (CYP3A4)

Fentanyl is primarily metabolized by the cytochrome P450 enzyme CYP3A4.

• CYP3A4 Inhibitors (e.g., macrolide antibiotics like erythromycin, azole antifungal agents like ketoconazole, and protease inhibitors like ritonavir) can increase fentanyl blood concentrations. This heightens and prolongs the risk of adverse reactions, including potentially fatal respiratory depression.
• CYP3A4 Inducers: Conversely, discontinuing an inducer can also increase fentanyl levels, requiring careful monitoring.

Other Important Interactions

• Serotonergic Drugs: Concomitant use with drugs that affect the serotonergic neurotransmitter system (e.g., certain antidepressants like SSRIs and SNRIs) may lead to Serotonin Syndrome, a potentially life-threatening condition.
• MAO Inhibitors: Caution is necessary if Fentanyl Citrate is administered to a patient who has received a Monoamine Oxidase (MAO) Inhibitor within 14 days, due to the risk of severe, unpredictable potentiation observed with other opioids.
• Opioid Analgesics: The use of Mixed Agonist/Antagonist or Partial Agonist Opioid Analgesics (e.g., pentazocine, nalbuphine) should be avoided as they may reduce the pain-relieving effect or precipitate opioid withdrawal symptoms.

Citrato de Fentanilo functions as a mu-opioid receptor (MOR) agonist, primarily targeting MORs distributed throughout the central nervous system, including the periaqueductal gray and the rostral ventromedial medulla. Upon administration, the molecule traverses the blood-brain barrier rapidly due to its lipophilicity and binds with high affinity and selectivity to the MORs. This interaction stabilizes the receptor in its active conformational state.

Activation of the G-protein coupled MOR initiates a signal transduction cascade. The activated receptor couples to inhibitory Gi/o proteins. This coupling leads to the inhibition of adenylate cyclase, which consequently reduces the intracellular concentration of cyclic adenosine monophosphate (cAMP). Simultaneously, the betagamma subunits of the activated G-protein facilitate two key intracellular consequences: they promote the opening of inwardly rectifying potassium channels and inhibit voltage-gated calcium channels. The influx of potassium ions hyperpolarizes the neuronal membrane, while the decreased calcium influx limits the release of various neurotransmitters, including substance P and glutamate.

Collectively, these cellular actions modulate signal transmission. The overall systemic physiological consequence is a depression of neuronal excitability and the attenuation of afferent nociceptive signaling within the spinal cord and supraspinal structures.

Citrato De Fentanilo administration is strictly defined by its intended clinical use, employing different routes and protocols. The medicine is administered through two primary methods: parenteral (Intravenous or Intramuscular) and transmucosal (oral cavity) dosage forms.

The injectable solution, utilized for anesthesia and perioperative pain control, is typically given intravenously as a bolus or infusion, or intramuscularly for premedication. Due to its potent action, the parenteral form is administered only by personnel trained in resuscitation and in settings where supportive equipment is readily available. Dosage ranges are calculated based on patient weight (e.g., in mu g/kg) and procedure complexity, with supplemental doses administered as required based on clinical assessment.

Specialized transmucosal dosage forms (e.g., lozenges, tablets) are used only in patients who are already opioid-tolerant. Clinical protocols involve a careful titration process starting at the lowest available strength (e.g., 100 mu g or 200 mu g) to determine the effective single unit dose. The transmucosal unit must be allowed to dissolve slowly across the mucous membrane and must not be chewed, swallowed whole, or split. Frequency of use is strictly limited; once the effective dose is found, the administration of treatment for new pain episodes must be separated by a minimum of 4 hours, and consumption for breakthrough episodes should generally not exceed four doses per day. For special populations, such as older or debilitated patients, initial parenteral dosages are reduced and subsequent titration handled with caution.

Citrato De Fentanilo: Recent Clinical Evidence

---

Evidence for Use in Managing Breakthrough Pain

Research for Citrato De Fentanilo includes studies focused on breakthrough pain, which is characterized by fluctuating or episodic manifestations of severe pain. The research exploring this medicine includes short-term Randomized Controlled Trials (RCTs), often utilizing a crossover design, and systematic reviews. The studies were designed to assess outcomes related to episodic or acute changes in pain intensity. Studies monitored and measured patient-reported outcomes, such as how quickly and substantially the feeling of physical discomfort was monitored during the study period, typically at short, defined time intervals (e.g., 5, 10, or 15 minutes). Research describes the measurements of patient-reported pain relief that were recorded in these studies.

---

Evidence in Acute Pain and Perioperative Care

Citrato De Fentanilo was studied for research scenarios involving acute pain, such as that experienced immediately following surgery, and research exploring its inclusion in anesthesia protocols. This evidence includes studies conducted during periods of increased symptom activity, primarily utilizing RCTs and systematic reviews. Research explored short-term changes in symptom intensity, with studies focused on outcomes related to functional imbalance, such as the requirement for additional pain medication. Studies monitored responses over defined time intervals, typically focusing on the intraoperative period and the first three days following the procedure.

---

Study Limitations and Research Gaps

While the research base is substantial in the areas of acute and episodic pain, certain structural limitations exist. For some patient cohorts, follow-up observations have lasted up to 12 months, yet data on the overall consistency of observed symptom patterns beyond this period are not fully established. Comparative evidence is lacking for direct comparisons between many of the different fentanyl formulations. Furthermore, studies have explored pain in the cancer setting, but data related to non-cancer chronic pain conditions are still emerging. The results apply only to the specific populations studied, and data for certain comorbidity groups, such as pregnant individuals, remain insufficient.

Key Studies & References Breakthrough Cancer Pain Management with Fentanyl Opioids - European Society of Medicine (Review discussing ROOs and trial structure)

Common questions about Citrato De Fentanilo (FAQ)

Q: What is the difference between prescription Citrato De Fentanilo and other forms of fentanyl?

The official product, Citrato De Fentanilo, is strictly regulated and approved for specific medical purposes under the oversight of government agencies like the FDA. Official documents classify it as a Schedule II controlled substance. This means its composition, manufacturing, and legal use are rigidly defined and controlled by regulatory standards.

Q: Is Citrato De Fentanilo used for treating non-cancer pain?

For the transmucosal dosage forms (e.g., lozenges or tablets), the indication is specifically for the management of breakthrough cancer pain in patients who are already opioid-tolerant. Official regulatory documents often list the use for non-malignant (non-cancer) pain as a non-covered use for these specialized dosage forms.

Q: Why is Citrato De Fentanilo classified as a Schedule II controlled substance?

Fentanyl is classified as a Schedule II controlled substance by authorities like the DEA. This legal status is assigned because the medicine has a high potential for abuse. Official documents indicate that the use of Schedule II drugs may potentially lead to severe psychological or physical dependence.

Q: What does 'opioid-tolerant' mean when referring to patient eligibility for this drug?

The requirement to be 'opioid-tolerant' is a crucial safety criterion for using the transmucosal forms of this medicine. Regulatory documents define this status based on a patient's existing daily intake of other pain medicines. For example, it is defined as taking a minimum of 60 mg of oral morphine daily, or 30 mg of oral oxycodone daily, or an equivalent dose of another opioid for a week or longer.

Q: Is drug dependence the same as addiction when using Citrato De Fentanilo as prescribed?

Regulatory information highlights the risks of addiction, abuse, and misuse associated with this drug. The official product labeling also describes physical dependence as a separate physiological state that develops with chronic use. Physical dependence is a biological adaptation that causes withdrawal symptoms if the medicine is suddenly stopped, but it is clinically distinct from abuse or addiction.

Q: Are there specific food or drinks, like grapefruit, that interact with this medicine?

Official patient counseling information indicates that consuming grapefruit or grapefruit juice should be avoided during treatment. This caution is advised because grapefruit can interfere with the way the body processes the medicine, which may increase the blood concentration of fentanyl and potentially lead to stronger effects.

Q: Is there a risk of breathing problems while sleeping when using Citrato De Fentanilo?

Official regulatory documents warn about the risk of sleep-related breathing disorders associated with opioid use. This may include central sleep apnea (CSA) and sleep-related hypoxemia (low oxygen levels during sleep). Studies indicate that the use of opioids can increase the risk of CSA in a dose-dependent manner.

Q: What are the signs of withdrawal if the drug is stopped too quickly?

Withdrawal is a risk if the medicine is stopped suddenly after a period of regular use. While product labeling mentions the symptoms of Neonatal Opioid Withdrawal Syndrome in infants, the full range of typical adult opioid withdrawal signs is not explicitly detailed in all patient-facing information.

Q: How do doctors monitor the effectiveness and safety of a patient using this drug?

Official documents emphasize the requirement for close patient monitoring, particularly during the initiation of treatment and when dosages are being adjusted (titration). This observation is necessary to check for signs of over-sedation or severe respiratory depression, as required by regulatory safety protocols.

Q: Are there official resources for patients to report side effects or adverse events?

The official resources of regulatory authorities encourage the reporting of any suspected adverse reactions or side effects. The product labeling includes instructions for patients to report problems directly to the national regulatory authority (such as the FDA or Health Canada) or to contact the drug manufacturer.

Q: What should be done if the pain relief from the medicine is suddenly less effective?

Official patient information indicates that the prescriber should be informed if the patient feels their pain is suddenly not controlled. This guidance applies when the pain increases, becomes worse, or if new pain is experienced while undergoing treatment.

Q: Is it true that this drug can cause changes in pupil size?

Official product information states that fentanyl can cause miosis, which is the constriction or narrowing of the pupils. Pinpoint pupils are also listed by regulatory sources as a potential symptom of overdose.

Q: Are there any limitations on operating machinery or driving while using this medication?

Regulatory patient counseling information includes explicit warnings that this medicine may impair a person's ability to drive or operate machinery. Official guidance states that patients should not perform potentially hazardous activities until they are fully aware of the drug's effects on their body.

Q: Is it safe to handle the medication, such as a patch, without a risk of accidental absorption?

Regulatory instructions state that when handling a transdermal patch, the adhesive surface must not be touched with bare hands, due to the risk of the medicine absorbing through the skin. The official guidance requires hands to be washed thoroughly with large amounts of clear water after applying or handling the unit.

Storage and Security

Citrato De Fentanilo must be kept in a secure location and remain out of the sight and reach of children and pets at all times due to the risk of accidental exposure. For formulations such as the injection solution, official guidance requires storage at a Controlled Room Temperature of 20 C to 25 C (68 F to 77 F), with the explicit instruction to protect from light and do not freeze.

Specific packaging rules mandate that transdermal patches and oral lozenges must not be removed from their sealed pouch until immediately prior to use.

Official Disposal Instructions

Disposal must prioritize immediate, irreversible destruction to prevent misuse or harm. The preferred method is to return unused or expired product to an authorized drug take-back program.

If a take-back option is not available, the product labeling for certain forms (like transdermal patches and lozenges) instructs patients to flush them down the toilet immediately. Patches must be folded sticky-sides together before flushing. This specific instruction is regulatory-mandated because the risk of accidental exposure to this potent opioid outweighs general environmental concerns. The product should not be placed in household trash.